{"id":9935,"date":"2026-04-13T07:25:16","date_gmt":"2026-04-13T07:25:16","guid":{"rendered":"https:\/\/oncomatryx.com\/?page_id=9935"},"modified":"2026-04-13T10:18:47","modified_gmt":"2026-04-13T10:18:47","slug":"plataforma-adc","status":"publish","type":"page","link":"https:\/\/oncomatryx.com\/es\/plataforma-adc\/","title":{"rendered":"Plataforma ADC"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"9935\" class=\"elementor elementor-9935\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6cf3cf4 back e-flex e-con-boxed e-con e-parent\" data-id=\"6cf3cf4\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;shape_divider_bottom&quot;:&quot;curve&quot;,&quot;shape_divider_bottom_negative&quot;:&quot;yes&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-shape elementor-shape-bottom\" aria-hidden=\"true\" data-negative=\"true\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n\t<path class=\"elementor-shape-fill\" d=\"M500,97C126.7,96.3,0.8,19.8,0,0v100l1000,0V1C1000,19.4,873.3,97.8,500,97z\"\/>\n<\/svg>\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4b2ecd9 e-con-full e-flex e-con e-child\" data-id=\"4b2ecd9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8e048d5 elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet_extra elementor-hidden-tablet elementor-hidden-mobile_extra elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"8e048d5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">adc platform<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-590388b elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet_extra elementor-hidden-tablet elementor-hidden-mobile_extra elementor-hidden-mobile elementor-widget elementor-widget-heading\" data-id=\"590388b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">adc platform<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-707ba96 elementor-widget-mobile__width-initial titulo-principal elementor-widget elementor-widget-heading\" data-id=\"707ba96\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\"><span class=\"letra-bold\">Nuestra plataforma<\/span><\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-03f87ff elementor-widget elementor-widget-text-editor\" data-id=\"03f87ff\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Oncomatryx ha desarrollado una plataforma propia de <strong>conjugados de anticuerpo-f\u00e1rmaco (ADCs) <\/strong>dirigidos contra el microambiente tumoral, una nueva generaci\u00f3n de f\u00e1rmacos para tratar tumores s\u00f3lidos metast\u00e1sicos incurables hasta ahora.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-909641f e-flex e-con-boxed e-con e-parent\" data-id=\"909641f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-3ee15b6 e-con-full e-flex e-con e-child\" data-id=\"3ee15b6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b571b97 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"b571b97\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">F\u00e1rmacos de Precisi\u00f3n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-52e2a6b elementor-widget elementor-widget-heading\" data-id=\"52e2a6b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\">TRATAMIENTO DE TUMORES INVASIVOS CON F\u00c1RMACOS DE PRECISI\u00d3N DIRIGIDOS AL ESTROMA<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-13a7e6e elementor-widget elementor-widget-text-editor\" data-id=\"13a7e6e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La medicina de precisi\u00f3n est\u00e1 marcando un hito en el campo de la oncolog\u00eda. F\u00e1rmacos basados en anticuerpos monoclonales humanos dise\u00f1ados espec\u00edficamente para atacar prote\u00ednas asociadas al c\u00e1ncer<strong>, est\u00e1n transformando radicalmente el tratamiento de esta enfermedad.<\/strong><\/p><p>Anticuerpos monoclonales humanos dirigidos contra dianas terap\u00e9uticas en las c\u00e9lulas epiteliales tumorales revolucionaron el tratamiento del c\u00e1ncer en los \u00faltimos a\u00f1os del Siglo XX. Ya en el S.XXI, nuevos anticuerpos terap\u00e9uticos dirigidos a potenciar la respuesta inmune contra el tumor demostraron eficacia en algunos tumores resistentes a la primera generaci\u00f3n de anticuerpos. Y la conjugaci\u00f3n de la primera generaci\u00f3n de anticuerpos con potentes f\u00e1rmacos citot\u00f3xicos gener\u00f3 una tercera oleada de f\u00e1rmacos biotecnol\u00f3gicos, ADCs, que aunaban la especificidad y seguridad de los anticuerpos con una potencia mucho mayor.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1c827f6 e-con-full e-flex e-con e-child\" data-id=\"1c827f6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4c3167d elementor-widget elementor-widget-image\" data-id=\"4c3167d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_scale_effect&quot;:&quot;yes&quot;,&quot;motion_fx_scale_direction&quot;:&quot;out-in-out&quot;,&quot;motion_fx_scale_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:5,&quot;sizes&quot;:[]},&quot;motion_fx_scale_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:20,&quot;end&quot;:63}},&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;laptop&quot;,&quot;tablet_extra&quot;,&quot;tablet&quot;,&quot;mobile_extra&quot;,&quot;mobile&quot;]}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"896\" height=\"896\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/microscopio.jpg\" class=\"attachment-full size-full wp-image-1232\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/microscopio.jpg 896w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/microscopio-300x300.jpg 300w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/microscopio-150x150.jpg 150w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/microscopio-768x768.jpg 768w\" sizes=\"(max-width: 896px) 100vw, 896px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d8582eb e-flex e-con-boxed e-con e-parent\" data-id=\"d8582eb\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-27510f3 e-con-full e-flex e-con e-child\" data-id=\"27510f3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0151046 elementor-widget elementor-widget-heading\" data-id=\"0151046\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"elementor-heading-title elementor-size-default\">NUESTRA INNOVADORA APROXIMACI\u00d3N: <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6235037 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"6235037\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">NUEVAS DIANAS. NUEVOS ANTICUERPOS. NUEVOS ADCs<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f2389dd elementor-widget elementor-widget-text-editor\" data-id=\"f2389dd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Desde el inicio de la \u00abguerra contra el c\u00e1ncer\u00bb hace casi cinco d\u00e9cadas, la Ciencia ha logrado avances significativos en la prevenci\u00f3n y tratamiento de etapas tempranas de esta enfermedad. Sin embargo, los avances han sido limitados en etapas avanzadas e invasivas del C\u00e1ncer.<\/p><p><strong>El campo de batalla debe ampliarse.<\/strong><\/p><p>Cada vez hay m\u00e1s evidencia que respalda el desarrollo de f\u00e1rmacos de precisi\u00f3n dirigidos no solo a las c\u00e9lulas epiteliales tumorales, sino tambi\u00e9n a los fibroblastos asociados al c\u00e1ncer (CAFs) en el microentorno tumoral.<\/p><p>En la pionera aproximaci\u00f3n terap\u00e9utica de Oncomatryx, <strong>ampliamos las estrategias de combate. <\/strong>Nos enfocamos en el <strong>desarrollo de nuevos anticuerpos terap\u00e9uticos y nuevos ADCs <\/strong>dirigidos a prote\u00ednas espec\u00edficas localizadas en el microambiente tumoral, m\u00e1s concretamente en los fibroblastos asociados al tumor. Este\u00a0 planteamiento representa una nueva frontera en el tratamiento del c\u00e1ncer, apuntando no a las c\u00e9lulas epiteliales tumorales, sino <strong>a las c\u00e9lulas estromales que promueven la invasi\u00f3n tumoral, la resistencia a los tratamientos y la supresi\u00f3n de la respuesta inmune contra el tumor<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b62c20f e-con-full e-flex e-con e-child\" data-id=\"b62c20f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c8459f1 elementor-widget elementor-widget-image\" data-id=\"c8459f1\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_scale_effect&quot;:&quot;yes&quot;,&quot;motion_fx_scale_direction&quot;:&quot;out-in-out&quot;,&quot;motion_fx_scale_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:2,&quot;sizes&quot;:[]},&quot;motion_fx_scale_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:32,&quot;end&quot;:71}},&quot;motion_fx_motion_fx_mouse&quot;:&quot;yes&quot;,&quot;motion_fx_mouseTrack_effect&quot;:&quot;yes&quot;,&quot;motion_fx_mouseTrack_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:1.9,&quot;sizes&quot;:[]},&quot;motion_fx_tilt_effect&quot;:&quot;yes&quot;,&quot;motion_fx_tilt_speed&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:2,&quot;sizes&quot;:[]},&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;laptop&quot;,&quot;tablet_extra&quot;,&quot;tablet&quot;,&quot;mobile_extra&quot;,&quot;mobile&quot;]}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"704\" height=\"704\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/03\/p1.png\" class=\"attachment-large size-large wp-image-595\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/03\/p1.png 704w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/03\/p1-300x300.png 300w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/03\/p1-150x150.png 150w\" sizes=\"(max-width: 704px) 100vw, 704px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-9b3ac0c e-flex e-con-boxed e-con e-parent\" data-id=\"9b3ac0c\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;gradient&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2a7499b elementor-widget elementor-widget-heading\" data-id=\"2a7499b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">NUESTRO DESAF\u00cdO EN EL MICROAMBIENTE TUMORAL<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-be192e4 elementor-widget elementor-widget-text-editor\" data-id=\"be192e4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><em>En el coraz\u00f3n de la resistencia de los tumores s\u00f3lidos metast\u00e1sicos se encuentra el intrincado microambiente tumoral, constituido por c\u00e9lulas endoteliales, c\u00e9lulas del sistema inmume y fibroblastos asociados al tumor (<strong>C<\/strong>ancer-<strong>A<\/strong>ssociated <strong>F<\/strong>ibroblasts o CAFs). Las c\u00e9lulas cancerosas interact\u00faan con este microambiente, volvi\u00e9ndose m\u00e1s resilientes y desafiando los enfoques terap\u00e9uticos convencionales.<\/em><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d373ec0 e-flex e-con-boxed e-con e-parent\" data-id=\"d373ec0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7f83f1d elementor-widget elementor-widget-heading\" data-id=\"7f83f1d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">UNA NUEVA GENERACI\u00d3N DE ADC <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f7c0cf2 elementor-widget elementor-widget-text-editor\" data-id=\"f7c0cf2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En Oncomatryx, estamos liderando una nueva revoluci\u00f3n, con una plataforma de ADCs dise\u00f1ada espec\u00edficamente para abordar el desaf\u00edo del microambiente de los tumores s\u00f3lidos metast\u00e1sicos.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ccf272e e-flex e-con-boxed e-con e-parent\" data-id=\"ccf272e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c64de1 e-con-full e-flex e-con e-child\" data-id=\"2c64de1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-5f51957 e-con-full e-flex e-con e-child\" data-id=\"5f51957\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-13c5b2c e-con-full e-flex e-con e-child\" data-id=\"13c5b2c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7ce8026 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"7ce8026\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">LAS CLAVES DE NUESTRA PLATAFORMA <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-18530ee elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"18530ee\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInLeft&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>1. Anticuerpos Selectivos para el Microambiente<\/strong>: Desarrollamos anticuerpos altamente selectivos, dise\u00f1ados para reconocer y dirigirse a prote\u00ednas espec\u00edficas en el microambiente tumoral, m\u00e1s concretamente en los Fibroblastos Asociados al Tumor. Una precisi\u00f3n que asegura que nuestro tratamiento se centre en el epicentro del desaf\u00edo.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a8d35c6 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"a8d35c6\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInLeft&quot;,&quot;_animation_delay&quot;:150}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>2. Nuestra propia carga citot\u00f3xica o<em> Payload<\/em><\/strong>: Las Citolisinas, nuestro propio Payload, son agentes citot\u00f3xicos dise\u00f1ados para maximizar el impacto terap\u00e9utico, evitar la resistencia, potenciar la respuesta antitumoral del sistema inmunol\u00f3gico y minimizar los efectos secundarios no deseados en los tejidos sanos circundantes.<\/p><p>Las Citolisinas fueron desarrollados en colaboraci\u00f3n con <strong>Tube Pharmaceuticals GmbH<\/strong>, una empresa biofarmac\u00e9utica austr\u00edaca liderada por el prestigioso qu\u00edmico alem\u00e1n <strong>Dr. Wolfgang Richter<\/strong>, y posteriormente adquirida por Oncomatryx en 2023.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-46c6fc7 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"46c6fc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInLeft&quot;,&quot;_animation_delay&quot;:300}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>3. Nuestra propia estrategia de conjugaci\u00f3n:<\/strong>\u00a0Hemos desarrollado una estrategia de conjugaci\u00f3n que proporciona una estabilidad inigualable a los ADC en el torrente sangu\u00edneo del paciente. Esta estabilidad evita la liberaci\u00f3n no espec\u00edfica de la carga terap\u00e9utica en la sangre, asegurando que el agente citot\u00f3xico llegue directamente a los fibroblastos en el microentorno tumoral. De este modo, se minimizan los efectos secundarios del tratamiento y se maximiza su eficacia.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7a79e03 e-con-full e-flex e-con e-child\" data-id=\"7a79e03\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-0b9a42d elementor-widget elementor-widget-image\" data-id=\"0b9a42d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"683\" height=\"1024\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/celula-tumoral.jpg\" class=\"elementor-animation-grow attachment-full size-full wp-image-1270\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/celula-tumoral.jpg 683w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/celula-tumoral-200x300.jpg 200w\" sizes=\"(max-width: 683px) 100vw, 683px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8b84d24 e-con-full e-flex e-con e-child\" data-id=\"8b84d24\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-ebef9e3 e-con-full e-flex e-con e-child\" data-id=\"ebef9e3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2e2efc9 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"2e2efc9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">LAS VENTAJAS \u00daNICAS DE NUESTRA PLATAFORMA <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4f067f1 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"4f067f1\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInRight&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>1. <\/strong><strong>Nos dirigimos al epicentro del problema<\/strong>: Nuestros ADCs se concentran en el microambiente cercano al tumor, atacando directamente las estrategias defensivas desarrolladas por las c\u00e9lulas tumorales.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1cf880f elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"1cf880f\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInRight&quot;,&quot;_animation_delay&quot;:150}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>2. <\/strong><strong>Conseguimos mayor eficacia<\/strong>: Complementamos la potencia citot\u00f3xica caracter\u00edstica de los ADCs, con un payload que no genera resistencia y que estimula la respuesta antitumoral del sistema inmune.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ccf10f3 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"ccf10f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInRight&quot;,&quot;_animation_delay&quot;:300}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>3. <\/strong><strong>Reducimos los efectos secundarios<\/strong>: La especificidad de expresi\u00f3n de nuestras dianas terap\u00e9uticas en los fibroblastos asociados al tumor y la imbatible estabilidad de nuestros ADCs en la sangre del paciente, se traducen en un tratamiento m\u00e1s seguro, m\u00e1s tolerable y una mejora en la calidad de vida de los pacientes al minimizar los efectos adversos.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-fa71105 e-con-full e-flex e-con e-child\" data-id=\"fa71105\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f0878d8 elementor-widget elementor-widget-image\" data-id=\"f0878d8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"683\" height=\"1024\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/paltaforma-antitumoral.jpg\" class=\"elementor-animation-grow attachment-full size-full wp-image-1269\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/paltaforma-antitumoral.jpg 683w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/paltaforma-antitumoral-200x300.jpg 200w\" sizes=\"(max-width: 683px) 100vw, 683px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ab5fabc e-flex e-con-boxed e-con e-parent\" data-id=\"ab5fabc\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;gradient&quot;,&quot;shape_divider_bottom&quot;:&quot;arrow&quot;,&quot;shape_divider_bottom_negative&quot;:&quot;yes&quot;,&quot;motion_fx_motion_fx_scrolling&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_effect&quot;:&quot;yes&quot;,&quot;motion_fx_opacity_level&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:2,&quot;sizes&quot;:[]},&quot;motion_fx_opacity_range&quot;:{&quot;unit&quot;:&quot;%&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:{&quot;start&quot;:43,&quot;end&quot;:53}},&quot;motion_fx_devices&quot;:[&quot;desktop&quot;,&quot;laptop&quot;,&quot;tablet_extra&quot;,&quot;tablet&quot;],&quot;motion_fx_opacity_direction&quot;:&quot;out-in&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-shape elementor-shape-bottom\" aria-hidden=\"true\" data-negative=\"true\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 700 10\" preserveAspectRatio=\"none\">\n\t<path class=\"elementor-shape-fill\" d=\"M360 0L350 9.9 340 0 0 0 0 10 700 10 700 0\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c687110 titulo-principal elementor-widget elementor-widget-heading\" data-id=\"c687110\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">PIPELINE<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ac1ed98 elementor-widget elementor-widget-text-editor\" data-id=\"ac1ed98\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Nuestra misi\u00f3n se centra en abordar necesidades m\u00e9dicas no cubiertas dentro del campo de la oncolog\u00eda, en particular tumores s\u00f3lidos metast\u00e1sicos resistentes a quimioterapias convencionales, sofisticadas inmunoterapias y modernos ADCs. Impulsados por la excelencia cient\u00edfica, trabajamos incansablemente para descubrir y desarrollar tratamientos eficaces. Nuestro pipeline refleja este compromiso con la innovaci\u00f3n y nuestra esperanza por marcar una diferencia significativa en la vida de los pacientes.<\/p><p>Te invitamos a conocer m\u00e1s sobre nuestro trabajo, nuestros ADCs dirigidos contra el microambiente tumoral, OMTX705, OMTX703 y OMTX707, sus avances y c\u00f3mo, juntos, estamos marcando el camino hacia un futuro donde el c\u00e1ncer pueda ser tratado de manera m\u00e1s eficaz y segura.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-39afbc0 elementor-hidden-mobile_extra elementor-hidden-mobile e-flex e-con-boxed e-con e-parent\" data-id=\"39afbc0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-e8dbbad e-con-full e-grid e-con e-child\" data-id=\"e8dbbad\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8a5db01 elementor-widget elementor-widget-text-editor\" data-id=\"8a5db01\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Precl\u00ednica<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0f44360 elementor-widget elementor-widget-text-editor\" data-id=\"0f44360\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 1<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5188879 elementor-widget elementor-widget-text-editor\" data-id=\"5188879\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 1\/2<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4559379 elementor-widget elementor-widget-text-editor\" data-id=\"4559379\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 2<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c903579 elementor-widget elementor-widget-text-editor\" data-id=\"c903579\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 2\/3<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-40a395d elementor-widget elementor-widget-text-editor\" data-id=\"40a395d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 3<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1b9390d elementor-widget elementor-widget-text-editor\" data-id=\"1b9390d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Comercializaci\u00f3n<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-68092e0 e-con-full e-flex e-con e-child\" data-id=\"68092e0\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ba37948 elementor-widget elementor-widget-progress\" data-id=\"ba37948\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-ba37948\">\n\t\t\t\t<b>OMTX705<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-ba37948\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"35\" aria-valuetext=\"35% (&lt;b&gt;Fase 1\/2&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"35\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Fase 1\/2<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7fc4e6b elementor-widget elementor-widget-n-accordion\" data-id=\"7fc4e6b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1330\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1330\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC) anti-FAP, primero en su categor\u00eda (FAP:CYT)  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1330\" class=\"elementor-element elementor-element-8ae3b48 e-con-full e-flex e-con e-child\" data-id=\"8ae3b48\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b540ea elementor-widget elementor-widget-text-editor\" data-id=\"5b540ea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>OMTX705 es un anticuerpo conjugado (ADC) dirigido contra FAP, actualmente en ensayos cl\u00ednicos de fase 1b\/2 para m\u00faltiples indicaciones: PDAC, MSS-CRC, NSC-Lung Cancer y sarcomas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-9a830f9 elementor-widget elementor-widget-progress\" data-id=\"9a830f9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-9a830f9\">\n\t\t\t\t<b>OMTX703<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-9a830f9\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"11\" aria-valuetext=\"11% (&lt;b&gt;Precl\u00ednica&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"11\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Precl\u00ednica<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-75a1e5e elementor-widget elementor-widget-n-accordion\" data-id=\"75a1e5e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1230\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1230\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC) anti-endoglina, primero en su categor\u00eda (ENG:CYT)  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1230\" class=\"elementor-element elementor-element-d1c2434 e-con-full e-flex e-con e-child\" data-id=\"d1c2434\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1815b97 elementor-widget elementor-widget-text-editor\" data-id=\"1815b97\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En desarrollo para el tratamiento de c\u00e1ncer g\u00e1strico, el sarcoma de Ewing y melanoma uveal.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e18f677 elementor-widget elementor-widget-progress\" data-id=\"e18f677\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-e18f677\">\n\t\t\t\t<b>OMTX707<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-e18f677\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"11\" aria-valuetext=\"11% (&lt;b&gt;Precl\u00ednica&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"11\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Precl\u00ednica<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-16aa415 elementor-widget elementor-widget-n-accordion\" data-id=\"16aa415\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-2370\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-2370\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC), primero en su categor\u00eda (TME:CYT) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-2370\" class=\"elementor-element elementor-element-5e2cf4f e-con-full e-flex e-con e-child\" data-id=\"5e2cf4f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8b825f8 elementor-widget elementor-widget-text-editor\" data-id=\"8b825f8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En desarrollo para el tratamiento de sarcomas y fibrosis.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1d4c3d6 elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet_extra elementor-hidden-tablet e-flex e-con-boxed e-con e-parent\" data-id=\"1d4c3d6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2cbfd51 e-con-full e-grid e-con e-child\" data-id=\"2cbfd51\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2d8473c elementor-widget elementor-widget-text-editor\" data-id=\"2d8473c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Precl\u00ednica<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b927135 elementor-widget elementor-widget-text-editor\" data-id=\"b927135\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 1<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a56094a elementor-widget elementor-widget-text-editor\" data-id=\"a56094a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 1\/2<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d44b23b elementor-widget elementor-widget-text-editor\" data-id=\"d44b23b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 2<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3bb7f1f elementor-widget elementor-widget-text-editor\" data-id=\"3bb7f1f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 2\/3<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b30b0b9 elementor-widget elementor-widget-text-editor\" data-id=\"b30b0b9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Fase 3<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a0d0303 elementor-widget elementor-widget-text-editor\" data-id=\"a0d0303\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p style=\"text-align: center;\">Comercializaci\u00f3n<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d6b878b e-con-full e-flex e-con e-child\" data-id=\"d6b878b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-05708f9 elementor-widget elementor-widget-progress\" data-id=\"05708f9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-05708f9\">\n\t\t\t\t<b>OMTX705<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-05708f9\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"41\" aria-valuetext=\"41% (&lt;b&gt;Fase 1\/2&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"41\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Fase 1\/2<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4801c5e elementor-widget elementor-widget-n-accordion\" data-id=\"4801c5e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-7550\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-7550\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC) anti-FAP, primero en su categor\u00eda (FAP:CYT)  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-7550\" class=\"elementor-element elementor-element-895a189 e-con-full e-flex e-con e-child\" data-id=\"895a189\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f50768b elementor-widget elementor-widget-text-editor\" data-id=\"f50768b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>OMTX705 es un anticuerpo conjugado (ADC) dirigido contra FAP, actualmente en ensayos cl\u00ednicos de fase 1b\/2 para m\u00faltiples indicaciones: PDAC, MSS-CRC, NSC-Lung Cancer y sarcomas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c3b199a elementor-widget elementor-widget-progress\" data-id=\"c3b199a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-c3b199a\">\n\t\t\t\t<b>OMTX703<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-c3b199a\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"30\" aria-valuetext=\"30% (&lt;b&gt;Precl\u00ednica&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"30\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Precl\u00ednica<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-97c10d8 elementor-widget elementor-widget-n-accordion\" data-id=\"97c10d8\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1590\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1590\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC) anti-endoglina, primero en su categor\u00eda (ENG:CYT)  <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1590\" class=\"elementor-element elementor-element-9102848 e-con-full e-flex e-con e-child\" data-id=\"9102848\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c3dd08a elementor-widget elementor-widget-text-editor\" data-id=\"c3dd08a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En desarrollo para el tratamiento de c\u00e1ncer g\u00e1strico, el sarcoma de Ewing y melanoma uveal.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-207175d elementor-widget elementor-widget-progress\" data-id=\"207175d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"progress.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<span class=\"elementor-title\" id=\"elementor-progress-bar-207175d\">\n\t\t\t\t<b>OMTX707<\/b>\t\t\t<\/span>\n\t\t\n\t\t<div aria-labelledby=\"elementor-progress-bar-207175d\" class=\"elementor-progress-wrapper\" role=\"progressbar\" aria-valuemin=\"0\" aria-valuemax=\"100\" aria-valuenow=\"30\" aria-valuetext=\"30% (&lt;b&gt;Precl\u00ednica&lt;\/b&gt;)\">\n\t\t\t<div class=\"elementor-progress-bar\" data-max=\"30\">\n\t\t\t\t<span class=\"elementor-progress-text\"><b>Precl\u00ednica<\/b><\/span>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a1b8e3f elementor-widget elementor-widget-n-accordion\" data-id=\"a1b8e3f\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-1690\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-1690\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> Anticuerpo conjugado (ADC), primero en su categor\u00eda (TME:CYT) <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewBox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-1690\" class=\"elementor-element elementor-element-4c7646e e-con-full e-flex e-con e-child\" data-id=\"4c7646e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bf5ae22 elementor-widget elementor-widget-text-editor\" data-id=\"bf5ae22\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En desarrollo para el tratamiento de sarcomas y fibrosis.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8c9206f e-flex e-con-boxed e-con e-parent\" data-id=\"8c9206f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-957ecc3 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"957ecc3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">OMTX705<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0411de9 elementor-widget elementor-widget-text-editor\" data-id=\"0411de9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La eficacia antitumoral de nuestro ADC anti-FAP, <em>OMTX705<\/em>, se demostr\u00f3 en dos laboratorios diferentes acad\u00e9micos y tres CROs, en varios modelos de c\u00e1ncer de p\u00e1ncreas, mama, ovario y pulm\u00f3n de ratones xenotransplantados con tumores derivados de pacientes. OMTX705 provoc\u00f3 una inhibici\u00f3n del crecimiento tumoral del 100% en solitario, alcanzando regresi\u00f3n tumoral completa en ratones con un sistema inmune humanizado y la mayor potencia en combinaci\u00f3n con inmunoterapia o quimioterapia.<\/p><p>OMTX705 est\u00e1 ya en fase cl\u00ednica en Europa y USA, lo que est\u00e1 permitiendo recopilar datos muy emocionantes sobre la seguridad y eficacia antitumoral en pacientes con tumores s\u00f3lidos metast\u00e1sicos incurables hasta ahora.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-932f5c3 e-flex e-con-boxed e-con e-parent\" data-id=\"932f5c3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f74240 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"2f74240\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>LA DIANA \u2192 \u00bfQU\u00c9 ES FAP?<\/h3><p>FAP (Fibroblast Activation Protein) es una glicoprote\u00edna de membrana de los fibroblastos asociados al tumor en el microambiente que le rodea. Estos fibroblastos asociados al tumor juegan un papel crucial en su invasividad, resistencia al tratamiento y supresi\u00f3n de la respuesta inmune antitumoral. Algunos puntos clave de FAP:<\/p><ul><li>Tiene una alta capacidad de internalizaci\u00f3n, facilitando la entrada del payload en el fibroblasto asociado al tumor.<\/li><li>Se sobreexpresa en el estroma peritumoral del 90% de los tumores s\u00f3lidos metast\u00e1sicos.<\/li><li>No se ha descrito expresi\u00f3n de FAP en tejidos sanos, salvo una expresi\u00f3n leve en adipocitos, m\u00fasculo liso, m\u00e9dula \u00f3sea y \u00fatero.<\/li><li>Est\u00e1 implicada en la remodelaci\u00f3n de la matriz extracelular, el crecimiento tumoral y la met\u00e1stasis.<\/li><\/ul><p>Enfoques anteriores que intentaban bloquear la actividad de FAP\u03b1 han fracasado en la Fase II debido a la falta de eficacia. Nuestro enfoque no busca bloquear FAP\u03b1, sino utilizarlo como un veh\u00edculo de internalizaci\u00f3n espec\u00edfico de los CAF para transportar mol\u00e9culas citot\u00f3xicas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-eef05a1 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"eef05a1\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>EL ANTICUERPO<\/h3><p>El anticuerpo monoclonal (mAb) IgG1 humanizado anti-FAP OMTX005 se une espec\u00edficamente, con valores sub-nanomolares de EC50 y de manera dependiente de la concentraci\u00f3n, a las prote\u00ednas FAP humana y de rat\u00f3n, (0.33 y 0.25 nM), expresadas en la membrana de c\u00e9lulas HT1080 transfectadas con FAP, fibroblastos primarios asociados a tumor de pacientes, as\u00ed como<em> in vivo<\/em> a FAP en fibroblastos del estroma tumoral de ratones xenotransplantados con tumores de p\u00e1ncreas derivados de pacientes, tras administraci\u00f3n intraperitoneal.<\/p><ul><li>La afinidad y especificidad del mAb humanizado OMTX005 no se ven alteradas por la conjugaci\u00f3n a la carga t\u00f3xica citolisina de Oncomatryx.<\/li><li>El mAb humanizado anti-FAP\u03b1 OMTX005 se internaliza r\u00e1pidamente al interior de las c\u00e9lulas (85% en 60 min).<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-efbcab7 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"efbcab7\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>LA CARGA T\u00d3XICA<\/h3><p><strong><u>Citolisinas sint\u00e9ticas<\/u><\/strong><\/p><ul><li>Inhibidoras de la polimerizaci\u00f3n de tubulina que bloquean la formaci\u00f3n del huso mit\u00f3tico. Tetrap\u00e9ptidos sint\u00e9ticos an\u00e1logos de las Tubolisinas naturales.<\/li><li>Bajo peso molecular: 780 g\/mol<\/li><li><strong>No son sustrato de las prote\u00ednas transportadores de f\u00e1rmacos Pgp-mediated (MultiDrug Resistance Proteins)<\/strong><\/li><li>Altamente citot\u00f3xicas<\/li><li>Anti-angiog\u00e9nicas<\/li><li>F\u00e1ciles de conjugar<\/li><li>Es factible obtener cantidad suficiente para desarrollo precl\u00ednico y cl\u00ednico mediante s\u00edntesis total<\/li><li>El grupo funcional para tecnolog\u00eda de enlace puede ser modificado<\/li><li>Pueden aplicarse distintas tecnolog\u00edas de enlace<\/li><li>Propiedad intelectual s\u00f3lida<\/li><\/ul><p>Se evaluaron in vitro y en modelos in vivo distintas combinaciones de citolisinas, linkers y spacers, y se seleccion\u00f3 la citolisina-TAM558 como la estructura \u00f3ptima para obtener la mayor actividad y estabilidad en sangre.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-26fedcf titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"26fedcf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Nuevo mecanismo de acci\u00f3n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-212987b elementor-widget elementor-widget-image\" data-id=\"212987b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1.webp\" data-elementor-open-lightbox=\"yes\" data-elementor-lightbox-title=\"novel moa\" data-e-action-hash=\"#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6OTA0NiwidXJsIjoiaHR0cHM6XC9cL29uY29tYXRyeXguY29tXC93cC1jb250ZW50XC91cGxvYWRzXC8yMDI1XC8wMVwvbm92ZWwtbW9hLTEud2VicCJ9\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"900\" height=\"428\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1-1024x487.webp\" class=\"attachment-large size-large wp-image-9046\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1-1024x487.webp 1024w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1-300x143.webp 300w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1-768x365.webp 768w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1-1536x730.webp 1536w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2025\/01\/novel-moa-1.webp 1688w\" sizes=\"(max-width: 900px) 100vw, 900px\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-8237ede e-flex e-con-boxed e-con e-parent\" data-id=\"8237ede\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a0b38e4 e-con-full e-flex e-con e-child\" data-id=\"a0b38e4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3bcfb61 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"3bcfb61\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Modelos murinos PDX<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-31e9bb0 elementor-widget elementor-widget-text-editor\" data-id=\"31e9bb0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>\u279f 100% de inhibici\u00f3n del crecimiento tumoral y regresi\u00f3n en modelos murinos PDX de c\u00e1ncer de p\u00e1ncreas, g\u00e1strico, ovario,mama triple negativo y pulm\u00f3n, con o sin sistemas inmunol\u00f3gicos humanizados, sin toxicidad significativa.<\/p><p>\u279f Superioridad demostrada tanto frente a la quimioterapia cl\u00e1sica como a los f\u00e1rmacos de inmunoterapia moderna disponibles en el mercado, tanto como agente \u00fanico como en terapias combinadas.<\/p><p>\u279f Superioridad demostrada frente a otros ADC dirigidos contra FAP, con cargas terap\u00e9uticas distintas.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-0ba4985 e-con-full e-flex e-con e-child\" data-id=\"0ba4985\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-879b8b2 elementor-widget elementor-widget-image\" data-id=\"879b8b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"620\" height=\"301\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-2.png\" class=\"attachment-large size-large wp-image-1414\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-2.png 620w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-2-300x146.png 300w\" sizes=\"(max-width: 620px) 100vw, 620px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-d8a81f7 e-flex e-con-boxed e-con e-parent\" data-id=\"d8a81f7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7c41d4c titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"7c41d4c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Toxicidad GLP en primates no humanos<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e955460 elementor-widget elementor-widget-text-editor\" data-id=\"e955460\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><strong>Toxicidad para dosis repetidas<\/strong><\/h3><p>\u279f Estudio no pivotal:<\/p><ul><li>Fase MTD: 6 niveles de dosis crecientes hasta 100 mg\/kg \u2192 Sin efectos adversos en ninguna dosis.<\/li><li>Fase FD: Dos dosis de 80 mg\/kg administrados en el d\u00eda 1 y el d\u00eda 8 \u2192 Sin efectos adversos. An\u00e1lisis TK: OMTX705 \u2013 Cmax: 2.180 \u00b5g\/mL; t1\/2: 54,5 h; AUC: 99.900 h*\u00b5g\/mL; CL: 0,696 mL\/h\/kg<\/li><\/ul><p>\u279f Estudio pivotal:<\/p><ul><li>Estudio GLP: Estudio GLP de toxicidad por dosis repetida de 28 d\u00edas en monos. OMTX705 administrado una vez por semana durante cuatro semanas, en dosis de 10, 30 y 80 mg\/kg.<\/li><li>No se observaron efectos adversos a ninguna de las dosis evaluadas.<\/li><li>No se detect\u00f3 exposici\u00f3n a Cytolysin en ninguna dosis de OMTX705.<\/li><li>80 mg\/kg fue considerado el NOAEL y el HNSTD en monos.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-ed4f33b e-flex e-con-boxed e-con e-parent\" data-id=\"ed4f33b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-bfdfd90 e-con-full e-flex e-con e-child\" data-id=\"bfdfd90\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-8126eba titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"8126eba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Ensayos cl\u00ednicos<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1c8ee84 elementor-widget elementor-widget-text-editor\" data-id=\"1c8ee84\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Ensayo de escalado de dosis en Fase I en tumores s\u00f3lidos altamente invasivos y leiomiosarcomas.<\/p><p>\u279f Objetivo primario: seguridad y tolerabilidad.<\/p><p>\u279f Dise\u00f1o de escalado de dosis 3+3.<\/p><p>\u279f Administraci\u00f3n como agente \u00fanico.<\/p><p>\u279f Combinaci\u00f3n con Pembrolizumab.<\/p><p>\u279f IND e IMPD aprobados.<\/p><p>\u279f Primer paciente tratado en la UE: octubre 2022.<\/p><p>\u279f Primer paciente tratado en EE.UU.: mayo 2023.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-74cef1d e-con-full e-flex e-con e-child\" data-id=\"74cef1d\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-697ee00 elementor-widget elementor-widget-image\" data-id=\"697ee00\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"766\" height=\"431\" src=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-4.png\" class=\"attachment-large size-large wp-image-1415\" alt=\"\" srcset=\"https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-4.png 766w, https:\/\/oncomatryx.com\/wp-content\/uploads\/2024\/04\/Grafico-4-300x169.png 300w\" sizes=\"(max-width: 766px) 100vw, 766px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-aa9d802 e-flex e-con-boxed e-con e-parent\" data-id=\"aa9d802\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b147329 titulo-secundario elementor-widget elementor-widget-heading\" data-id=\"b147329\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">COMPANION DX<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ee32ef elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"7ee32ef\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3><span style=\"text-decoration: underline;\">INVASCAN<\/span>: diagn\u00f3stico y pron\u00f3stico de tumores invasivos<\/h3><p>InvaScan es una <strong>nueva y precisa herramienta para el diagn\u00f3stico y pron\u00f3stico de tumores invasivos<\/strong>. Es un sistema de tinci\u00f3n inmunohistoqu\u00edmica de tejidos, basado en un anticuerpo monoclonal que detecta Collagen XI-\u03b11 en muestras de biopsia de carcinomas invasivos, optimizado para su uso en las plataformas habituales de los servicios de anatom\u00eda patol\u00f3gica.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4091551 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"4091551\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3>VENTAJAS T\u00c9CNICAS<\/h3><ol><li>Es espec\u00edfico para COL11A1 y <strong>no presenta reacci\u00f3n cruzada con otros col\u00e1genos similares, como el COL5A1<\/strong>. Adem\u00e1s, marca de forma clara los fibroblastos asociados al tumor.<\/li><li><strong>Detecta COL11A1 en muestras de distintos tejidos<\/strong> con alta sensibilidad, especificidad y reproducibilidad.<\/li><li>Est\u00e1 <strong>optimizado para ser utilizado en las plataformas de tinci\u00f3n automatizadas de uso com\u00fan<\/strong> en los laboratorios de patolog\u00eda, facilitando su implementaci\u00f3n en la rutina cl\u00ednica.<\/li><li><strong>Validaciones multic\u00e9ntricas en Europa y EEUU<\/strong> han demostrado su utilidad cl\u00ednica para diagnosticar o pronosticar c\u00e1ncer de colon, p\u00e1ncreas, ri\u00f1\u00f3n, mama ovario y cabeza y cuello.<\/li><\/ol><p>COL11A1 tambi\u00e9n ha sido descrito como un <strong>biomarcador \u00fatil para el diagn\u00f3stico, pron\u00f3stico y predicci\u00f3n de quimiorresistencia<\/strong> de varios tipos de tumores diferentes:<\/p><ul><li>C\u00e1ncer de P\u00e1ncreas: Se detect\u00f3 COL11A1 en el estroma desmopl\u00e1sico de los adenocarcinomas ductales pancre\u00e1ticos, diferenci\u00e1ndolos de la pancreatitis cr\u00f3nica y los carcinomas ampulares. <em>(Garc\u00eda-Pravia et al. 2013. PloS ONE 8(10): 1-13).<\/em><\/li><li>C\u00e1ncer de Colon: Se identific\u00f3 COL11A1 en el estroma de p\u00f3lipos col\u00f3nicos con componente maligno, permitiendo diferenciarlos de los p\u00f3lipos benignos. <em>(Galv\u00e1n JA. et al. BMC Cancer 2014; 14:867).<\/em><\/li><li>C\u00e1ncer de Mama: Se encontr\u00f3 COL11A1 en el estroma desmopl\u00e1sico de los carcinomas infiltrantes, diferenci\u00e1ndolos de las lesiones inflamatorias y esclerosantes benignas. DMTX invaScan facilita el diagn\u00f3stico de tumores mamarios infiltrantes en biopsias con alta sensibilidad y especificidad. <em>(Fuentes-Mart\u00ednez N. et al. Histol Histopathol. 2015; 30(1):87-93).<\/em><\/li><li>Papilomas Mamarios: Pron\u00f3stico de recurrencia y progresi\u00f3n maligna de lesiones papilares mamarias no malignas. Validado mediante IHC en biopsias con aguja gruesa de papilomas intraductales mamarios que fueron extirpados y seguidos por m\u00e1s de 5 a\u00f1os. <em>(Freire J. et al. BioMed Research International 2015; In Press).<\/em><\/li><li>C\u00e1ncer de Cabeza y Cuello: Se detect\u00f3 COL11A1 en el estroma desmopl\u00e1sico de carcinomas escamosos, diferenci\u00e1ndolos de lesiones benignas como fibrosis, inflamaci\u00f3n, leucoqueratosis, \u00falceras e hiperplasia.<\/li><li>C\u00e1ncer de Ri\u00f1\u00f3n: Se identific\u00f3 COLLAGEN XI-\u03b1-1 en el estroma desmopl\u00e1sico de los carcinomas renales, diferenci\u00e1ndolos de oncocitomas.<\/li><li>C\u00e1ncer de Pulm\u00f3n: Se detect\u00f3 COLLAGEN XI-\u03b1-1 en el estroma desmopl\u00e1sico de adenocarcinomas con patr\u00f3n lep\u00eddico, facilitando la diferenciaci\u00f3n entre adenocarcinomas in situ y fibrosis pulmonar.<\/li><li>C\u00e1ncer de Ovario: Se identific\u00f3 COL11A1 en tumores malignos de ovario, diferenci\u00e1ndolos de tumores benignos y lesiones no malignas. Adem\u00e1s, COLLAGEN XI-\u03b1-1 es \u00fatil para evaluar la invasividad de los implantes tumorales borderline. Se ha correlacionado el aumento de la expresi\u00f3n de COL11A1 con mayor invasividad tumoral, met\u00e1stasis y recurrencia. <em>(Cheon, DJ. et al. Clin Cancer Res. 2014; 20(3):711-723).<\/em><\/li><li>C\u00e1ncer de Vejiga: Se detect\u00f3 COL11A1 en el estroma de carcinomas invasivos de vejiga (pT2), diferenci\u00e1ndolos de tumores superficiales y lesiones benignas. <em>(Freire et al. 2014. Pathology Journal of the RCPA. 46:S135).<\/em><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c8deba2 elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"c8deba2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInUp&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Adem\u00e1s \u2026\u2026<\/strong><\/p><h3>Companion Diagnostics de los f\u00e1rmacos de precisi\u00f3n de Oncomatryx<\/h3><p>Estamos desarrollando y validando Kits de Diagn\u00f3stico para identificar y monitorizar a los pacientes susceptibles de beneficiarse del tratamiento con nuestros f\u00e1rmacos de precisi\u00f3n dirigidos al microambiente tumoral.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>adc platform adc platform Nuestra plataforma Oncomatryx ha desarrollado una plataforma propia de conjugados de anticuerpo-f\u00e1rmaco (ADCs) dirigidos contra el microambiente tumoral, una nueva generaci\u00f3n de f\u00e1rmacos para tratar tumores s\u00f3lidos metast\u00e1sicos incurables hasta ahora. F\u00e1rmacos de Precisi\u00f3n TRATAMIENTO DE TUMORES INVASIVOS CON F\u00c1RMACOS DE PRECISI\u00d3N DIRIGIDOS AL ESTROMA La medicina de precisi\u00f3n est\u00e1 marcando &#8230; <a title=\"Plataforma ADC\" class=\"read-more\" href=\"https:\/\/oncomatryx.com\/es\/plataforma-adc\/\" aria-label=\"Leer m\u00e1s sobre Plataforma ADC\">Leer m\u00e1s<\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-9935","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/pages\/9935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/comments?post=9935"}],"version-history":[{"count":126,"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/pages\/9935\/revisions"}],"predecessor-version":[{"id":10260,"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/pages\/9935\/revisions\/10260"}],"wp:attachment":[{"href":"https:\/\/oncomatryx.com\/es\/wp-json\/wp\/v2\/media?parent=9935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}